EUVIMEDEUVIMED entdecken
Crossref

2‐Phenylbenzothiazoles featuring heteroaryl sulfonamide end‐capping substructures as developable mPGES‐1 inhibitors

Tansu Yalçın, Paul M Jordan iD, Abdurrahman Olğaç iD, Philipp Dahlke, Tuğçe Gür Maz, Erden Banoglu iD, Oliver Werz iD, Burcu Çalışkan iD

Archiv der Pharmazie · 2025

DOI: 10.1002/ardp.202400756 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Tansu Yalçın und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, Ankara, Turkey. Hauptthemen laut MEDLINE: Prostaglandin-E Synthases, Sulfonamides, Benzothiazoles, Enzyme Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: The Scientific and Technological Research Council of Turkey (TUBITAK), Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The inhibition of human microsomal prostaglandin E 2 (PGE 2 ) synthase‐1 (mPGES‐1) is a promising therapeutic modality for developing next‐generation anti‐inflammatory medications. In this study, we present novel 2‐phenylbenzothiazole derivatives featuring heteroaryl sulfonamide end‐capping substructures as inhibitors of human mPGES‐1, with IC 50 values in the range of 0.72–3.40 µM in a cell‐free assay of PGE 2 formation. Notably, compound 21 , featuring a quinoxalinedione ring in its sulfonamide segment, effectively suppresses PGE 2 biosynthesis at a low micromolar concentration (IC 50 = 0.72 µM) with exceptional selectivity against cyclooxygenase (COX)‐1, COX‐2, 5‐lipoxygenase (5‐LOX), and FLAP. This compound offers a novel chemical scaffold for developing safer and more effective anti‐inflammatory agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostaglandin-E SynthasesSulfonamidesBenzothiazolesEnzyme InhibitorsHumansStructure-Activity RelationshipMolecular StructureDose-Response Relationship, DrugDinoprostoneInhibitory Concentration 50

Stichwörter der Autor:innen

anti‐inflammatorybenzothiazolecyclooxygenaseprostaglandinsulfonamide

Substanzen

Prostaglandin-E SynthasesPTGES protein, humanSulfonamidesBenzothiazolesDinoprostoneEnzyme Inhibitors

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, Ankara, Turkey.
  • Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich Schiller University Jena, Jena, Germany.
  • Jena Center for Soft Matter (JCSM), Friedrich Schiller University Jena, Jena, Germany.

ORCID-Profile: Paul M Jordan, Abdurrahman Olğaç, Erden Banoglu, Oliver Werz, Burcu Çalışkan

Förderung

  • The Scientific and Technological Research Council of Turkey (TUBITAK)
  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Yalçın, T., Jordan, P. M., Olğaç, A., Dahlke, P., Maz, T. G., Banoglu, E., Werz, O., & Çalışkan, B. (2025). 2‐Phenylbenzothiazoles featuring heteroaryl sulfonamide end‐capping substructures as developable mPGES‐1 inhibitors. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400756

Vancouver

Yalçın T, Jordan PM, Olğaç A, Dahlke P, Maz TG, Banoglu E, et al. 2‐Phenylbenzothiazoles featuring heteroaryl sulfonamide end‐capping substructures as developable mPGES‐1 inhibitors. Archiv der Pharmazie. 2025. doi:10.1002/ardp.202400756

BibTeX
@article{Yaln2025,
  author = {Yalçın, Tansu and Jordan, Paul M and Olğaç, Abdurrahman and Dahlke, Philipp and Maz, Tuğçe Gür and Banoglu, Erden and Werz, Oliver and Çalışkan, Burcu},
  title = {2‐Phenylbenzothiazoles featuring heteroaryl sulfonamide end‐capping substructures as developable mPGES‐1 inhibitors},
  journal = {Archiv der Pharmazie},
  year = {2025},
  doi = {10.1002/ardp.202400756}
}
Kostenlos starten →